| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triiodothyronine | 45 | 2023 | 54 | 6.050 |
Why?
|
| Thyroid Gland | 22 | 2024 | 28 | 5.040 |
Why?
|
| Thyroid Neoplasms | 13 | 2025 | 15 | 4.280 |
Why?
|
| Symporters | 19 | 2024 | 21 | 4.270 |
Why?
|
| Receptors, Thyroid Hormone | 31 | 2023 | 33 | 4.180 |
Why?
|
| Thyroid Hormones | 27 | 2023 | 30 | 3.960 |
Why?
|
| Thyroxine | 24 | 2025 | 33 | 3.850 |
Why?
|
| Hypothyroidism | 26 | 2026 | 48 | 3.760 |
Why?
|
| Thyrotropin | 32 | 2024 | 51 | 3.400 |
Why?
|
| Animals | 74 | 2026 | 1875 | 3.380 |
Why?
|
| Thyroid Hormone Receptors alpha | 8 | 2021 | 9 | 2.730 |
Why?
|
| Pregnancy Complications | 11 | 2017 | 44 | 2.480 |
Why?
|
| Thyroid Hormone Receptors beta | 8 | 2023 | 8 | 2.450 |
Why?
|
| Humans | 102 | 2025 | 6794 | 2.390 |
Why?
|
| Neurons | 6 | 2025 | 50 | 2.300 |
Why?
|
| Tretinoin | 17 | 2012 | 30 | 2.020 |
Why?
|
| Thyroid Diseases | 17 | 2017 | 25 | 1.850 |
Why?
|
| Mice | 28 | 2026 | 746 | 1.770 |
Why?
|
| Gene Expression Regulation | 17 | 2019 | 120 | 1.750 |
Why?
|
| Iodine | 7 | 2024 | 11 | 1.700 |
Why?
|
| Signal Transduction | 11 | 2024 | 246 | 1.600 |
Why?
|
| Breast Neoplasms | 8 | 2011 | 170 | 1.570 |
Why?
|
| Hyperthyroidism | 8 | 2024 | 18 | 1.500 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2025 | 2 | 1.480 |
Why?
|
| Sumoylation | 4 | 2021 | 4 | 1.480 |
Why?
|
| Promoter Regions, Genetic | 21 | 2021 | 45 | 1.470 |
Why?
|
| Iodine Radioisotopes | 9 | 2024 | 11 | 1.250 |
Why?
|
| Pregnancy | 17 | 2024 | 599 | 1.240 |
Why?
|
| Muscle, Skeletal | 3 | 2026 | 75 | 1.190 |
Why?
|
| Female | 44 | 2024 | 4060 | 1.130 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2018 | 20 | 1.100 |
Why?
|
| Mutation | 13 | 2021 | 97 | 1.080 |
Why?
|
| Male | 39 | 2026 | 3671 | 1.070 |
Why?
|
| Neurogenesis | 4 | 2025 | 13 | 1.050 |
Why?
|
| Cell Proliferation | 6 | 2021 | 143 | 1.000 |
Why?
|
| COUP Transcription Factor I | 3 | 2018 | 3 | 0.940 |
Why?
|
| Gliosis | 1 | 2025 | 2 | 0.930 |
Why?
|
| Astrocytes | 1 | 2025 | 9 | 0.930 |
Why?
|
| Membrane Proteins | 6 | 2013 | 48 | 0.860 |
Why?
|
| Hypothalamus | 2 | 2024 | 49 | 0.840 |
Why?
|
| Rats | 29 | 2017 | 571 | 0.820 |
Why?
|
| Cell Line | 19 | 2018 | 124 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2012 | 88 | 0.820 |
Why?
|
| Zebrafish | 1 | 2023 | 5 | 0.810 |
Why?
|
| Intelligence | 2 | 2014 | 2 | 0.810 |
Why?
|
| Base Sequence | 20 | 2015 | 65 | 0.800 |
Why?
|
| Perchlorates | 2 | 2014 | 2 | 0.770 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2014 | 93 | 0.770 |
Why?
|
| Neoplasm Proteins | 3 | 2013 | 18 | 0.770 |
Why?
|
| Adipose Tissue, White | 1 | 2021 | 9 | 0.720 |
Why?
|
| Regeneration | 2 | 2026 | 5 | 0.710 |
Why?
|
| Carrier Proteins | 9 | 2004 | 28 | 0.710 |
Why?
|
| DNA-Binding Proteins | 5 | 2002 | 38 | 0.700 |
Why?
|
| Neuroprotection | 1 | 2021 | 2 | 0.700 |
Why?
|
| Protein Isoforms | 5 | 2023 | 12 | 0.690 |
Why?
|
| Iodides | 8 | 2009 | 8 | 0.690 |
Why?
|
| Adipocytes | 3 | 2021 | 31 | 0.660 |
Why?
|
| Kidney Failure, Chronic | 7 | 2022 | 420 | 0.640 |
Why?
|
| Muscle Development | 2 | 2021 | 19 | 0.630 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2011 | 21 | 0.630 |
Why?
|
| Cerebral Cortex | 2 | 2019 | 15 | 0.630 |
Why?
|
| Environmental Exposure | 3 | 2016 | 12 | 0.620 |
Why?
|
| Antineoplastic Agents | 6 | 2011 | 72 | 0.620 |
Why?
|
| Cell Differentiation | 5 | 2015 | 101 | 0.620 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 8 | 0.620 |
Why?
|
| Renal Dialysis | 10 | 2022 | 457 | 0.610 |
Why?
|
| Cells, Cultured | 9 | 2018 | 234 | 0.610 |
Why?
|
| Oxygen | 1 | 2019 | 44 | 0.610 |
Why?
|
| Thermogenesis | 3 | 2014 | 8 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 8 | 2025 | 258 | 0.590 |
Why?
|
| RNA, Messenger | 19 | 2015 | 190 | 0.580 |
Why?
|
| Genes, Reporter | 4 | 2011 | 13 | 0.580 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2009 | 19 | 0.570 |
Why?
|
| Cell Line, Tumor | 10 | 2011 | 156 | 0.560 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 2 | 2021 | 3 | 0.560 |
Why?
|
| Cognition Disorders | 2 | 2018 | 19 | 0.560 |
Why?
|
| Response Elements | 5 | 2012 | 8 | 0.550 |
Why?
|
| Aging | 2 | 2017 | 105 | 0.550 |
Why?
|
| Pyramidal Cells | 1 | 2018 | 2 | 0.550 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 4 | 0.550 |
Why?
|
| Thyroid Function Tests | 12 | 2019 | 17 | 0.550 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2017 | 4 | 0.540 |
Why?
|
| Stem Cells | 4 | 2004 | 19 | 0.540 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2024 | 293 | 0.530 |
Why?
|
| Sarcopenia | 1 | 2017 | 19 | 0.520 |
Why?
|
| Brain Injuries | 1 | 2017 | 12 | 0.520 |
Why?
|
| Luciferases | 5 | 2008 | 10 | 0.510 |
Why?
|
| Cell Membrane | 2 | 2013 | 54 | 0.490 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 4 | 2021 | 4 | 0.490 |
Why?
|
| Neoplasms | 3 | 2012 | 92 | 0.480 |
Why?
|
| Adipose Tissue, Brown | 2 | 2009 | 16 | 0.480 |
Why?
|
| Transcription Factors | 6 | 2009 | 53 | 0.470 |
Why?
|
| Myoblasts, Skeletal | 1 | 2015 | 1 | 0.470 |
Why?
|
| Brain | 6 | 2018 | 94 | 0.460 |
Why?
|
| Cell Nucleus | 5 | 2018 | 38 | 0.430 |
Why?
|
| Transfection | 17 | 2008 | 56 | 0.430 |
Why?
|
| Blotting, Western | 6 | 2018 | 110 | 0.430 |
Why?
|
| MAP Kinase Signaling System | 2 | 2011 | 11 | 0.430 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 59 | 0.430 |
Why?
|
| Energy Metabolism | 1 | 2014 | 21 | 0.420 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2005 | 9 | 0.410 |
Why?
|
| Muscular Diseases | 2 | 2026 | 5 | 0.410 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 6 | 0.410 |
Why?
|
| Research Design | 1 | 2014 | 41 | 0.410 |
Why?
|
| Mitochondrial Proteins | 3 | 2009 | 15 | 0.410 |
Why?
|
| Ion Channels | 3 | 2009 | 14 | 0.410 |
Why?
|
| Serpins | 2 | 2011 | 5 | 0.400 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 172 | 0.380 |
Why?
|
| SUMO-1 Protein | 1 | 2012 | 1 | 0.380 |
Why?
|
| Ubiquitins | 1 | 2012 | 14 | 0.380 |
Why?
|
| Molecular Sequence Data | 16 | 2006 | 70 | 0.380 |
Why?
|
| Adult | 14 | 2025 | 2113 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 12 | 0.370 |
Why?
|
| Growth Hormone | 9 | 2000 | 25 | 0.370 |
Why?
|
| Carcinoma, Papillary | 2 | 2002 | 3 | 0.370 |
Why?
|
| Osteoblasts | 2 | 2002 | 4 | 0.370 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 11 | 0.360 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2011 | 2 | 0.360 |
Why?
|
| Gene Expression | 8 | 2018 | 77 | 0.360 |
Why?
|
| Phosphorylation | 3 | 2018 | 73 | 0.360 |
Why?
|
| Adaptation, Physiological | 2 | 2009 | 13 | 0.360 |
Why?
|
| Receptors, Retinoic Acid | 7 | 2009 | 12 | 0.350 |
Why?
|
| Aged | 16 | 2023 | 1539 | 0.350 |
Why?
|
| Up-Regulation | 2 | 2017 | 94 | 0.350 |
Why?
|
| Genetic Vectors | 3 | 2008 | 19 | 0.340 |
Why?
|
| Models, Animal | 2 | 2021 | 23 | 0.330 |
Why?
|
| Water Supply | 1 | 2010 | 6 | 0.330 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 3 | 0.330 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 9 | 0.330 |
Why?
|
| Apoptosis | 5 | 2019 | 179 | 0.320 |
Why?
|
| Maternal Exposure | 1 | 2010 | 17 | 0.320 |
Why?
|
| DNA | 6 | 2023 | 39 | 0.310 |
Why?
|
| Mice, Mutant Strains | 2 | 2021 | 10 | 0.300 |
Why?
|
| Prospective Studies | 6 | 2023 | 331 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 10 | 2003 | 72 | 0.290 |
Why?
|
| Acetates | 2 | 2015 | 6 | 0.290 |
Why?
|
| Phenols | 2 | 2015 | 9 | 0.290 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 231 | 0.290 |
Why?
|
| Graves Disease | 1 | 2008 | 3 | 0.280 |
Why?
|
| Adipose Tissue | 2 | 2012 | 69 | 0.280 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 2005 | 2 | 0.280 |
Why?
|
| Catecholamines | 2 | 2009 | 7 | 0.280 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 14 | 0.280 |
Why?
|
| United States | 9 | 2025 | 1019 | 0.280 |
Why?
|
| CREB-Binding Protein | 2 | 2021 | 2 | 0.280 |
Why?
|
| Immunoprecipitation | 2 | 2018 | 12 | 0.280 |
Why?
|
| Thyrotoxicosis | 5 | 2017 | 6 | 0.260 |
Why?
|
| Mutant Proteins | 1 | 2006 | 2 | 0.260 |
Why?
|
| PPAR alpha | 1 | 2006 | 9 | 0.250 |
Why?
|
| Peritoneal Dialysis | 2 | 2018 | 48 | 0.250 |
Why?
|
| Fatty Acids | 1 | 2006 | 25 | 0.250 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2024 | 3 | 0.250 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2004 | 34 | 0.240 |
Why?
|
| Spatial Memory | 1 | 2025 | 1 | 0.230 |
Why?
|
| Trans-Activators | 2 | 2002 | 10 | 0.230 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2004 | 29 | 0.230 |
Why?
|
| Microglia | 1 | 2025 | 5 | 0.230 |
Why?
|
| Recovery of Function | 1 | 2025 | 11 | 0.230 |
Why?
|
| Diabetic Nephropathies | 2 | 2017 | 56 | 0.220 |
Why?
|
| Plasmids | 7 | 2008 | 17 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 1 | 2004 | 24 | 0.220 |
Why?
|
| Fetal Development | 1 | 2005 | 28 | 0.220 |
Why?
|
| Radionuclide Imaging | 3 | 2012 | 4 | 0.220 |
Why?
|
| Disease Progression | 3 | 2018 | 170 | 0.220 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2002 | 8 | 0.210 |
Why?
|
| Middle Aged | 12 | 2020 | 2108 | 0.210 |
Why?
|
| Terminology as Topic | 2 | 2014 | 15 | 0.210 |
Why?
|
| Transcription, Genetic | 6 | 2010 | 40 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2008 | 90 | 0.200 |
Why?
|
| Iodide Peroxidase | 4 | 2011 | 5 | 0.200 |
Why?
|
| Veterans | 3 | 2019 | 70 | 0.200 |
Why?
|
| Gene Targeting | 2 | 2002 | 3 | 0.200 |
Why?
|
| 5' Flanking Region | 1 | 2002 | 1 | 0.190 |
Why?
|
| Ovalbumin | 1 | 2002 | 2 | 0.190 |
Why?
|
| Transcriptome | 2 | 2021 | 31 | 0.190 |
Why?
|
| Protein Kinases | 1 | 2002 | 5 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 19 | 0.190 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 2021 | 19 | 0.190 |
Why?
|
| Pituitary Gland | 3 | 2021 | 40 | 0.190 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 44 | 0.180 |
Why?
|
| Disease | 1 | 2002 | 1 | 0.180 |
Why?
|
| Risk Factors | 6 | 2020 | 767 | 0.180 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 50 | 0.180 |
Why?
|
| Osteocalcin | 1 | 2001 | 1 | 0.180 |
Why?
|
| Organogenesis | 2 | 2012 | 7 | 0.180 |
Why?
|
| Vascular Diseases | 1 | 2021 | 10 | 0.170 |
Why?
|
| Sympathetic Nervous System | 1 | 2001 | 7 | 0.170 |
Why?
|
| Uncoupling Protein 1 | 3 | 2009 | 12 | 0.170 |
Why?
|
| COUP Transcription Factor II | 1 | 2021 | 1 | 0.170 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 59 | 0.170 |
Why?
|
| Models, Biological | 2 | 2012 | 64 | 0.170 |
Why?
|
| Drug Resistance | 4 | 2015 | 16 | 0.170 |
Why?
|
| Sodium Iodide | 1 | 2000 | 1 | 0.160 |
Why?
|
| Coronary Artery Disease | 1 | 2022 | 85 | 0.160 |
Why?
|
| PAX8 Transcription Factor | 3 | 2008 | 3 | 0.160 |
Why?
|
| Paired Box Transcription Factors | 3 | 2008 | 3 | 0.160 |
Why?
|
| Body Weight | 3 | 2014 | 90 | 0.160 |
Why?
|
| Cyclic AMP | 3 | 2002 | 30 | 0.160 |
Why?
|
| Nuclear Proteins | 4 | 2002 | 17 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2021 | 285 | 0.160 |
Why?
|
| Transcriptional Activation | 2 | 2006 | 9 | 0.160 |
Why?
|
| Kinetics | 4 | 2002 | 69 | 0.160 |
Why?
|
| Mortality | 3 | 2017 | 43 | 0.160 |
Why?
|
| Organ Specificity | 3 | 2010 | 10 | 0.160 |
Why?
|
| Time Factors | 6 | 2017 | 321 | 0.160 |
Why?
|
| 5-Methylcytosine | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pituitary Neoplasms | 3 | 2015 | 14 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 282 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2019 | 26 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 3 | 0.150 |
Why?
|
| Triglycerides | 3 | 2015 | 58 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2006 | 45 | 0.150 |
Why?
|
| Incidence | 4 | 2017 | 197 | 0.150 |
Why?
|
| Hippocampus | 2 | 2017 | 19 | 0.150 |
Why?
|
| Blood Glucose | 2 | 2017 | 188 | 0.140 |
Why?
|
| Chromones | 2 | 2008 | 6 | 0.140 |
Why?
|
| Morpholines | 2 | 2008 | 6 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 15 | 0.140 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2018 | 1 | 0.140 |
Why?
|
| Nestin | 1 | 2018 | 1 | 0.140 |
Why?
|
| Isotope Labeling | 1 | 2018 | 2 | 0.140 |
Why?
|
| Cell Survival | 1 | 2018 | 33 | 0.140 |
Why?
|
| Binding Sites | 7 | 2002 | 24 | 0.140 |
Why?
|
| Chickens | 6 | 2002 | 8 | 0.130 |
Why?
|
| Brain Edema | 1 | 2017 | 3 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 8 | 0.130 |
Why?
|
| Hypoxia, Brain | 1 | 2017 | 4 | 0.130 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2017 | 4 | 0.130 |
Why?
|
| Dexamethasone | 2 | 2005 | 30 | 0.130 |
Why?
|
| Mental Health | 1 | 2017 | 70 | 0.120 |
Why?
|
| Reference Values | 3 | 2002 | 56 | 0.120 |
Why?
|
| DNA Primers | 2 | 2015 | 23 | 0.120 |
Why?
|
| Isoenzymes | 2 | 2011 | 15 | 0.120 |
Why?
|
| Autoantibodies | 2 | 2017 | 12 | 0.120 |
Why?
|
| Endocrine Disruptors | 1 | 2016 | 3 | 0.120 |
Why?
|
| Retinoid X Receptors | 3 | 2010 | 7 | 0.120 |
Why?
|
| Heart Rate | 2 | 2009 | 29 | 0.120 |
Why?
|
| Retinoids | 2 | 2006 | 4 | 0.120 |
Why?
|
| Depression | 1 | 2017 | 128 | 0.120 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 2 | 0.120 |
Why?
|
| RNA Interference | 1 | 2015 | 11 | 0.120 |
Why?
|
| Thyroidectomy | 2 | 2022 | 6 | 0.120 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2008 | 8 | 0.120 |
Why?
|
| Cholesterol | 2 | 2014 | 37 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 13 | 0.120 |
Why?
|
| Quality of Life | 1 | 2017 | 184 | 0.120 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 2015 | 1 | 0.110 |
Why?
|
| Hormone Replacement Therapy | 2 | 2014 | 17 | 0.110 |
Why?
|
| Adenoma | 1 | 2015 | 7 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2003 | 155 | 0.110 |
Why?
|
| Intra-Abdominal Fat | 1 | 2015 | 5 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2015 | 4 | 0.110 |
Why?
|
| Adiponectin | 1 | 2015 | 6 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2009 | 39 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 43 | 0.110 |
Why?
|
| Kidney | 5 | 2024 | 184 | 0.110 |
Why?
|
| Body Composition | 1 | 2015 | 47 | 0.110 |
Why?
|
| Contrast Media | 1 | 2014 | 18 | 0.110 |
Why?
|
| PPAR gamma | 1 | 2015 | 51 | 0.110 |
Why?
|
| Antithyroid Agents | 3 | 2008 | 5 | 0.110 |
Why?
|
| Carbohydrate Metabolism | 1 | 2014 | 10 | 0.110 |
Why?
|
| Alkaline Phosphatase | 1 | 1994 | 33 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 497 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2006 | 24 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 84 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2024 | 681 | 0.100 |
Why?
|
| Blotting, Northern | 4 | 2003 | 25 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2003 | 17 | 0.100 |
Why?
|
| Cause of Death | 3 | 2020 | 82 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 29 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 169 | 0.100 |
Why?
|
| Thyrotropin, beta Subunit | 1 | 2012 | 1 | 0.100 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Receptor Cross-Talk | 1 | 2012 | 5 | 0.100 |
Why?
|
| Hep G2 Cells | 1 | 2012 | 7 | 0.100 |
Why?
|
| Glycerolphosphate Dehydrogenase | 2 | 2003 | 2 | 0.090 |
Why?
|
| Cold Temperature | 2 | 2003 | 5 | 0.090 |
Why?
|
| Norepinephrine | 2 | 2003 | 10 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 23 | 0.090 |
Why?
|
| Thyroid Nuclear Factor 1 | 2 | 2002 | 3 | 0.090 |
Why?
|
| Osteosarcoma | 2 | 2002 | 3 | 0.090 |
Why?
|
| Selenium | 1 | 2011 | 2 | 0.090 |
Why?
|
| Pregnancy Trimesters | 1 | 2011 | 2 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2011 | 3 | 0.090 |
Why?
|
| Disease Management | 2 | 2025 | 33 | 0.090 |
Why?
|
| Prognosis | 3 | 2019 | 220 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 208 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2001 | 150 | 0.090 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2010 | 20 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2025 | 67 | 0.090 |
Why?
|
| Publications | 1 | 2011 | 5 | 0.090 |
Why?
|
| Liver | 2 | 2003 | 157 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 2002 | 9 | 0.090 |
Why?
|
| Proline | 3 | 2015 | 5 | 0.090 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2011 | 34 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2008 | 11 | 0.090 |
Why?
|
| Protein Binding | 1 | 2011 | 29 | 0.080 |
Why?
|
| Sulfobromophthalein | 1 | 2010 | 1 | 0.080 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2010 | 1 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 2 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 15 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 17 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 63 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2002 | 45 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2009 | 10 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 13 | 0.080 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2002 | 7 | 0.080 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2009 | 2 | 0.080 |
Why?
|
| COS Cells | 1 | 2009 | 3 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2002 | 5 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 27 | 0.070 |
Why?
|
| Amino Acid Sequence | 4 | 1998 | 38 | 0.070 |
Why?
|
| Lithium | 1 | 1989 | 4 | 0.070 |
Why?
|
| Erythrocytes | 1 | 1989 | 14 | 0.070 |
Why?
|
| Sodium | 1 | 1989 | 43 | 0.070 |
Why?
|
| Point Mutation | 3 | 2005 | 5 | 0.070 |
Why?
|
| Cycloheximide | 1 | 2008 | 5 | 0.070 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 2 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 1988 | 44 | 0.070 |
Why?
|
| Caco-2 Cells | 1 | 2008 | 3 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 16 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2008 | 38 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2008 | 3 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 140 | 0.070 |
Why?
|
| Calcium | 1 | 1988 | 117 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 1986 | 6 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2008 | 31 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2004 | 5 | 0.070 |
Why?
|
| Potassium Iodide | 1 | 2007 | 1 | 0.070 |
Why?
|
| Proprotein Convertase 2 | 2 | 2005 | 25 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 18 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2001 | 17 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2004 | 16 | 0.060 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2006 | 1 | 0.060 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2006 | 1 | 0.060 |
Why?
|
| Glycogen | 1 | 2006 | 10 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 19 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 33 | 0.060 |
Why?
|
| California | 2 | 2017 | 230 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2005 | 50 | 0.060 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2026 | 1 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2006 | 59 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 20 | 0.060 |
Why?
|
| Heterozygote | 2 | 2003 | 9 | 0.060 |
Why?
|
| Hypoparathyroidism | 1 | 2005 | 1 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 4 | 1996 | 5 | 0.060 |
Why?
|
| Carcinoma | 1 | 2005 | 13 | 0.060 |
Why?
|
| Phenotype | 2 | 2003 | 91 | 0.060 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2005 | 2 | 0.060 |
Why?
|
| Histidine | 2 | 2003 | 2 | 0.060 |
Why?
|
| Ligands | 1 | 2005 | 17 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 7 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2005 | 20 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 47 | 0.060 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2004 | 1 | 0.060 |
Why?
|
| Synaptotagmin II | 1 | 2004 | 1 | 0.060 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 2004 | 1 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2004 | 4 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2004 | 10 | 0.060 |
Why?
|
| Age Distribution | 1 | 2005 | 45 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2004 | 6 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 25 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2005 | 65 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 11 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2001 | 23 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 118 | 0.050 |
Why?
|
| Proprotein Convertase 1 | 1 | 2004 | 18 | 0.050 |
Why?
|
| Mutagenesis | 2 | 2005 | 8 | 0.050 |
Why?
|
| Postpartum Period | 2 | 2017 | 14 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2003 | 57 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2004 | 27 | 0.050 |
Why?
|
| Prevalence | 1 | 2005 | 259 | 0.050 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2003 | 1 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Hyperthyroxinemia | 1 | 2003 | 1 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2003 | 4 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2017 | 500 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2003 | 7 | 0.050 |
Why?
|
| Receptors, Adrenergic | 1 | 2003 | 2 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2003 | 3 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 8 | 0.050 |
Why?
|
| Malate Dehydrogenase | 2 | 2001 | 2 | 0.050 |
Why?
|
| Lipolysis | 1 | 2003 | 13 | 0.050 |
Why?
|
| Leptin | 1 | 2003 | 21 | 0.050 |
Why?
|
| Glucose | 1 | 2003 | 50 | 0.050 |
Why?
|
| Coleoptera | 1 | 2003 | 1 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2003 | 36 | 0.050 |
Why?
|
| Medicare | 1 | 2023 | 57 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2002 | 13 | 0.050 |
Why?
|
| Myosin Light Chains | 1 | 2002 | 2 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2002 | 6 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2016 | 199 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2002 | 7 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 24 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 40 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2002 | 16 | 0.050 |
Why?
|
| Thyroglobulin | 1 | 2022 | 2 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2002 | 48 | 0.050 |
Why?
|
| Insulin | 1 | 2003 | 146 | 0.050 |
Why?
|
| Mitochondria | 1 | 2002 | 37 | 0.050 |
Why?
|
| Sp1 Transcription Factor | 1 | 2002 | 3 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 1 | 2002 | 1 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2002 | 4 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2002 | 7 | 0.050 |
Why?
|
| Escherichia coli | 2 | 1992 | 8 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2002 | 45 | 0.050 |
Why?
|
| Biological Transport | 2 | 2014 | 22 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2001 | 1 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2001 | 5 | 0.040 |
Why?
|
| Genome | 1 | 2001 | 7 | 0.040 |
Why?
|
| Biomarkers | 2 | 2017 | 214 | 0.040 |
Why?
|
| Myoblasts | 1 | 2021 | 7 | 0.040 |
Why?
|
| Uracil | 1 | 2001 | 2 | 0.040 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2001 | 12 | 0.040 |
Why?
|
| Subtilisins | 1 | 2000 | 9 | 0.040 |
Why?
|
| Oxytocin | 1 | 2000 | 6 | 0.040 |
Why?
|
| Colforsin | 1 | 2000 | 7 | 0.040 |
Why?
|
| Prolactin | 1 | 2000 | 23 | 0.040 |
Why?
|
| Bone Development | 1 | 2000 | 3 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2000 | 8 | 0.040 |
Why?
|
| Heart | 1 | 2000 | 25 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2020 | 67 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 98 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 111 | 0.040 |
Why?
|
| Sexuality | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cognition | 1 | 2018 | 30 | 0.040 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 1997 | 3 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 1997 | 6 | 0.030 |
Why?
|
| Proteins | 1 | 1997 | 41 | 0.030 |
Why?
|
| Muramidase | 2 | 1994 | 4 | 0.030 |
Why?
|
| Calcium Gluconate | 2 | 2005 | 2 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2017 | 3 | 0.030 |
Why?
|
| Lactation | 1 | 2017 | 11 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 18 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1996 | 1 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 28 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2017 | 14 | 0.030 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1996 | 6 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2004 | 72 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2017 | 18 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 83 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 165 | 0.030 |
Why?
|
| Pancreas | 1 | 1997 | 144 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 197 | 0.030 |
Why?
|
| Macromolecular Substances | 2 | 1996 | 5 | 0.030 |
Why?
|
| Flame Retardants | 1 | 2016 | 1 | 0.030 |
Why?
|
| Pesticides | 1 | 2016 | 1 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 280 | 0.030 |
Why?
|
| Reproductive Health | 1 | 2016 | 9 | 0.030 |
Why?
|
| Critical Care | 2 | 1986 | 10 | 0.030 |
Why?
|
| Hyperpituitarism | 1 | 2015 | 1 | 0.030 |
Why?
|
| Threonine | 1 | 2015 | 2 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 6 | 0.030 |
Why?
|
| Aurothioglucose | 1 | 1995 | 1 | 0.030 |
Why?
|
| Gold Sodium Thiomalate | 1 | 1995 | 1 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 1995 | 4 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1995 | 6 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 35 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2005 | 7 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 95 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1991 | 7 | 0.030 |
Why?
|
| Alleles | 1 | 1994 | 22 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1994 | 11 | 0.030 |
Why?
|
| Methimazole | 1 | 1994 | 1 | 0.030 |
Why?
|
| Skin Abnormalities | 1 | 1994 | 2 | 0.030 |
Why?
|
| Genetic Therapy | 2 | 2006 | 13 | 0.030 |
Why?
|
| Comorbidity | 1 | 2014 | 147 | 0.030 |
Why?
|
| Child | 1 | 2015 | 524 | 0.020 |
Why?
|
| Cholecalciferol | 1 | 1992 | 8 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 4 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 8 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 1989 | 22 | 0.020 |
Why?
|
| Genes, Bacterial | 1 | 1991 | 1 | 0.020 |
Why?
|
| Growth Substances | 1 | 1991 | 10 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 49 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2011 | 3 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 19 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2011 | 20 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 1989 | 1 | 0.020 |
Why?
|
| Aldosterone | 1 | 1989 | 8 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1989 | 25 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 3 | 1996 | 3 | 0.020 |
Why?
|
| RNA Splicing | 1 | 1989 | 6 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 1989 | 7 | 0.020 |
Why?
|
| Genes | 1 | 1989 | 2 | 0.020 |
Why?
|
| Potassium | 1 | 1989 | 26 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1988 | 5 | 0.020 |
Why?
|
| Edetic Acid | 1 | 1988 | 3 | 0.020 |
Why?
|
| Electrolytes | 1 | 1988 | 5 | 0.020 |
Why?
|
| Cattle | 1 | 1988 | 13 | 0.020 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1988 | 2 | 0.020 |
Why?
|
| Vitamin D | 1 | 1988 | 45 | 0.020 |
Why?
|
| Hypertension | 1 | 1989 | 147 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2006 | 1 | 0.020 |
Why?
|
| Talc | 1 | 1986 | 1 | 0.020 |
Why?
|
| Random Allocation | 1 | 1986 | 27 | 0.020 |
Why?
|
| Bystander Effect | 1 | 2006 | 1 | 0.020 |
Why?
|
| Iron-Binding Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Autoantigens | 1 | 2006 | 2 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2006 | 3 | 0.020 |
Why?
|
| Connexin 43 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2005 | 13 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 7 | 0.010 |
Why?
|
| Retinoid X Receptor beta | 1 | 2005 | 2 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 13 | 0.010 |
Why?
|
| Dopamine | 1 | 1984 | 12 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1984 | 19 | 0.010 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 1984 | 29 | 0.010 |
Why?
|
| Carcinoma, Medullary | 1 | 2003 | 1 | 0.010 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2003 | 2 | 0.010 |
Why?
|
| Femur | 1 | 2003 | 4 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2003 | 3 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 18 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2003 | 9 | 0.010 |
Why?
|
| Bone Density | 1 | 2003 | 25 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2003 | 55 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 118 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 51 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 112 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 187 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 268 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 2002 | 3 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 15 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 2 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2002 | 2 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 9 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2002 | 10 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 48 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2002 | 56 | 0.010 |
Why?
|
| Nuclear Matrix | 1 | 2001 | 1 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2001 | 2 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2001 | 17 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 53 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 3 | 0.010 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2001 | 17 | 0.010 |
Why?
|
| Proprotein Convertases | 1 | 2001 | 14 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2000 | 3 | 0.010 |
Why?
|
| Electrophoresis | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 18 | 0.010 |
Why?
|
| Isotretinoin | 1 | 2000 | 4 | 0.010 |
Why?
|
| TRPP Cation Channels | 1 | 1997 | 1 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 46 | 0.010 |
Why?
|
| Gestational Age | 1 | 1997 | 58 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1997 | 112 | 0.010 |
Why?
|
| Genomic Library | 1 | 1996 | 2 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 10 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 9 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1996 | 2 | 0.010 |
Why?
|
| Arthritis, Psoriatic | 1 | 1995 | 1 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1995 | 12 | 0.010 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1994 | 1 | 0.010 |
Why?
|
| Teratogens | 1 | 1994 | 1 | 0.010 |
Why?
|
| Propylthiouracil | 1 | 1994 | 2 | 0.010 |
Why?
|
| Child Development | 1 | 1994 | 21 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1989 | 11 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1989 | 33 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 5 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 7 | 0.000 |
Why?
|
| Myocardium | 1 | 1988 | 25 | 0.000 |
Why?
|
| Chromosome Deletion | 1 | 1987 | 6 | 0.000 |
Why?
|